CN106661614A - 确定癌症侵袭性、预后和治疗响应 - Google Patents

确定癌症侵袭性、预后和治疗响应 Download PDF

Info

Publication number
CN106661614A
CN106661614A CN201580024894.0A CN201580024894A CN106661614A CN 106661614 A CN106661614 A CN 106661614A CN 201580024894 A CN201580024894 A CN 201580024894A CN 106661614 A CN106661614 A CN 106661614A
Authority
CN
China
Prior art keywords
genes
expression level
overexpressed
underexpressed
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580024894.0A
Other languages
English (en)
Chinese (zh)
Inventor
F·亚尔-埃杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014900813A external-priority patent/AU2014900813A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CN106661614A publication Critical patent/CN106661614A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580024894.0A 2014-03-11 2015-03-11 确定癌症侵袭性、预后和治疗响应 Pending CN106661614A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2014900813A AU2014900813A0 (en) 2014-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014900813 2014-03-11
AU2014901212 2014-04-03
AU2014901212A AU2014901212A0 (en) 2014-04-03 Determining cancer agressiveness, prognosis and responsiveness to treatment
AU2014904716 2014-11-21
AU2014904716A AU2014904716A0 (en) 2014-11-21 Determining cancer agressiveness, prognosis and responsiveness to treatment
PCT/AU2015/050096 WO2015135035A2 (en) 2014-03-11 2015-03-11 Determining cancer agressiveness, prognosis and responsiveness to treatment

Publications (1)

Publication Number Publication Date
CN106661614A true CN106661614A (zh) 2017-05-10

Family

ID=54072534

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580024894.0A Pending CN106661614A (zh) 2014-03-11 2015-03-11 确定癌症侵袭性、预后和治疗响应

Country Status (11)

Country Link
US (1) US20170107577A1 (https=)
EP (1) EP3119908A4 (https=)
JP (1) JP2017508469A (https=)
KR (1) KR20160132067A (https=)
CN (1) CN106661614A (https=)
AU (1) AU2015230677A1 (https=)
BR (1) BR112016020897A2 (https=)
CA (1) CA2941769A1 (https=)
MX (1) MX2016011612A (https=)
SG (2) SG11201607448PA (https=)
WO (1) WO2015135035A2 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107868825A (zh) * 2017-11-21 2018-04-03 山东省千佛山医院 一种诊治肺腺癌的分子标记物
CN108704135A (zh) * 2018-05-24 2018-10-26 江苏大学附属医院 Chaf1a抑制剂在制备胃癌治疗药物中的用途
CN108841959A (zh) * 2018-07-12 2018-11-20 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN108866189A (zh) * 2018-07-12 2018-11-23 吉林大学 一种喉鳞状细胞癌易感性预测试剂盒及系统
CN109593771A (zh) * 2018-07-27 2019-04-09 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN111370056A (zh) * 2019-05-22 2020-07-03 深圳思勤医疗科技有限公司 确定待测样本预定染色体不稳定指数的方法、系统和计算机可读介质
CN112133369A (zh) * 2020-08-26 2020-12-25 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CN113502329A (zh) * 2021-07-12 2021-10-15 隋雨桐 检测腺苷受体a2b表达量的试剂在制备肺腺癌的诊断和/或预后试剂盒中的应用
CN114540500A (zh) * 2022-03-21 2022-05-27 深圳市陆为生物技术有限公司 评价乳腺癌患者整体生存的产品
CN115369173A (zh) * 2022-09-23 2022-11-22 河北医科大学第三医院 基因标志物组合在预测膀胱尿路上皮癌预后中的应用
WO2025092879A1 (zh) * 2023-10-31 2025-05-08 南京安吉生物科技有限公司 Gemin4基因及Gemin4蛋白在肿瘤中的应用
CN120290720A (zh) * 2025-04-11 2025-07-11 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120594831A (zh) * 2025-05-30 2025-09-05 南方医科大学南方医院 细胞外囊泡膜蛋白在制备早期胃癌诊断试剂盒中的应用
US12592320B2 (en) 2023-06-09 2026-03-31 Seekin, Inc. Methods of detecting cancer

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP3143160B1 (en) * 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3377646A1 (en) * 2015-11-20 2018-09-26 Université de Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
EP4715067A2 (en) * 2015-11-20 2026-03-25 Université de Strasbourg Method for identifying personalized therapeutic strategies for patients affected with a cancer
MX2018009368A (es) * 2016-02-01 2018-09-05 Bayer Pharma AG Biomarcadores para copanlisib.
GB201608000D0 (en) 2016-05-06 2016-06-22 Oxford Biodynamics Ltd Chromosome detection
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US11672801B2 (en) 2016-10-19 2023-06-13 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for treating cancer
WO2018152585A1 (en) * 2017-02-23 2018-08-30 The Council Of The Queensland Institute Of Medical Research "biomarkers for diagnosing conditions"
WO2018161081A1 (en) * 2017-03-03 2018-09-07 Board Of Regents, The University Of Texas System Gene signatures to predict drug response in cancer
CN110678928A (zh) * 2017-03-28 2020-01-10 南托米克斯有限责任公司 使用PARADIGM对miRNA诱导的乳腺癌中的沉默进行建模
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
WO2018183762A1 (en) 2017-03-29 2018-10-04 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating cancer
US10854338B2 (en) * 2017-03-29 2020-12-01 Imaging Endpoints II LLC Predicting breast cancer responsiveness to hormone treatment using quantitative textural analysis
EP3606518A4 (en) * 2017-04-01 2021-04-07 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
EP3879535B1 (en) * 2017-06-13 2024-12-11 BostonGene Corporation Systems and methods for identifying cancer treatments from normalized biomarker scores
JP2020524169A (ja) * 2017-06-20 2020-08-13 ジ・インスティチュート・オブ・キャンサー・リサーチ：ロイヤル・キャンサー・ホスピタル 方法および医学的利用
GB201709840D0 (en) * 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
SG11202000132WA (en) * 2017-07-10 2020-02-27 Univ Cornell Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
EP3695408B1 (en) * 2017-10-02 2026-01-21 The Broad Institute, Inc. Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
US11851712B2 (en) 2018-03-06 2023-12-26 Board Of Regents, The University Of Texas System Replication stress response biomarkers for immunotherapy response
JP2021522848A (ja) * 2018-05-15 2021-09-02 オンコロジー ベンチャー アーペーエス 癌患者における薬物応答性を予測する方法
CN108949984B (zh) * 2018-07-25 2022-01-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 基因desi2在三阴乳腺癌诊断、预后评估及治疗中的应用
CN110787296B (zh) * 2018-08-01 2024-04-16 复旦大学附属肿瘤医院 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer
CN110286219A (zh) * 2019-04-16 2019-09-27 福建师范大学 死亡相关蛋白激酶1在制备肾透明细胞癌术后预后评估试剂盒中的应用
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
US11715565B2 (en) * 2019-11-08 2023-08-01 Tempus Labs, Inc. Evaluating effect of event on condition using propensity scoring
EP4106879A4 (en) * 2020-02-19 2024-02-21 United States Government as Represented by The Department of Veterans Affairs IDENTIFICATION OF AN EGFR-BIN3 PATHWAY FOR ACTIVE SUPPRESSION OF INVASION AND REDUCTION OF TUMOR SIZE IN GLIOBLASTOMA
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2022011425A1 (en) * 2020-07-15 2022-01-20 Queensland University Of Technology Determining cancer responsiveness to treatment
CA3192695A1 (en) * 2020-09-16 2022-03-24 Novigenix Sa Biomarkers for immune checkpoint inhibitors treatment
CN112111575B (zh) * 2020-09-22 2023-01-10 重庆医科大学附属第一医院 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用
GB2628478A (en) 2020-10-29 2024-09-25 Ambergen Inc Novel photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes
JP7830464B2 (ja) * 2020-11-23 2026-03-16 サノフイ 乳がんにおける内分泌療法のモニタリングに使用するためのｅｒ制御遺伝子のパネル
CA3196872A1 (en) * 2020-12-23 2022-06-30 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t cells
WO2022217060A1 (en) * 2021-04-09 2022-10-13 Cardiff Oncology, Inc. Cancer treatment using parp inhibitors and plk1 inhibitors
CN113292643A (zh) * 2021-05-31 2021-08-24 南京市第二医院 一种肝癌肿瘤标志物及其应用
CN113355419B (zh) * 2021-06-28 2022-02-18 广州中医药大学(广州中医药研究院) 一种乳腺癌预后风险预测标志组合物及应用
AU2022406744A1 (en) * 2021-12-08 2024-07-11 Mayo Foundation For Medical Education And Research Assessing and treating melanoma
CN120536581B (zh) * 2025-06-19 2026-04-17 十堰市太和医院（湖北医药学院附属医院） Ul16结合蛋⽩2作为结直肠癌标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320443T3 (es) * 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
CA2556890C (en) * 2004-02-20 2017-04-25 Veridex, Llc Breast cancer prognostics
JP2005270093A (ja) * 2004-02-24 2005-10-06 Nippon Medical School 乳癌の術後予後予測に関与する遺伝子
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
BRPI0716391A2 (pt) * 2006-09-05 2017-01-31 Veridex Llc método de previsão de metástase distante de câncer de mama primário nódulo linfático-negativo usando análise de expressão gênica de via biloógica
US8273534B2 (en) * 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
WO2010129965A1 (en) * 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9863935B2 (en) * 2012-05-08 2018-01-09 H. Lee Moffitt Cancer And Research Institute, Inc. Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013163134A2 (en) * 2012-04-23 2013-10-31 The Trustees Of Columbia University In The City Of New York Biomolecular events in cancer revealed by attractor metagenes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENISE M. WOLF,ET AL: "Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity", 《PLOS ONE》 *
MARILLA C. PENDER-CUDLIP，ET AL: "Delta-6-desaturase activity and arachidonic acid synthesis are increased in human breast cancer tissue", 《THE OFFICIAL JOURNAL OF THE JAPANESE CANCER ASSOCIATION》 *
WEI-YI CHENG，ET AL: "Biomolecular Events in Cancer Revealed by Attractor Metagenes", 《PLOS COMPUTATIONAL BIOLOGY》 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107868825A (zh) * 2017-11-21 2018-04-03 山东省千佛山医院 一种诊治肺腺癌的分子标记物
CN108704135A (zh) * 2018-05-24 2018-10-26 江苏大学附属医院 Chaf1a抑制剂在制备胃癌治疗药物中的用途
CN108841959A (zh) * 2018-07-12 2018-11-20 吉林大学 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统
CN108866189A (zh) * 2018-07-12 2018-11-23 吉林大学 一种喉鳞状细胞癌易感性预测试剂盒及系统
CN109593771B (zh) * 2018-07-27 2022-03-29 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN109593771A (zh) * 2018-07-27 2019-04-09 四川大学华西医院 一种人类map2k5第1100位碱基突变基因及其检测试剂盒
CN111370056A (zh) * 2019-05-22 2020-07-03 深圳思勤医疗科技有限公司 确定待测样本预定染色体不稳定指数的方法、系统和计算机可读介质
CN112133369A (zh) * 2020-08-26 2020-12-25 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CN112133369B (zh) * 2020-08-26 2023-09-22 吴安华 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法
CN113502329A (zh) * 2021-07-12 2021-10-15 隋雨桐 检测腺苷受体a2b表达量的试剂在制备肺腺癌的诊断和/或预后试剂盒中的应用
CN114540500A (zh) * 2022-03-21 2022-05-27 深圳市陆为生物技术有限公司 评价乳腺癌患者整体生存的产品
CN115369173A (zh) * 2022-09-23 2022-11-22 河北医科大学第三医院 基因标志物组合在预测膀胱尿路上皮癌预后中的应用
US12592320B2 (en) 2023-06-09 2026-03-31 Seekin, Inc. Methods of detecting cancer
WO2025092879A1 (zh) * 2023-10-31 2025-05-08 南京安吉生物科技有限公司 Gemin4基因及Gemin4蛋白在肿瘤中的应用
CN120290720A (zh) * 2025-04-11 2025-07-11 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120594831A (zh) * 2025-05-30 2025-09-05 南方医科大学南方医院 细胞外囊泡膜蛋白在制备早期胃癌诊断试剂盒中的应用

Also Published As

Publication number Publication date
KR20160132067A (ko) 2016-11-16
JP2017508469A (ja) 2017-03-30
CA2941769A1 (en) 2015-09-17
AU2015230677A1 (en) 2016-10-27
US20170107577A1 (en) 2017-04-20
SG11201607448PA (en) 2016-10-28
WO2015135035A2 (en) 2015-09-17
EP3119908A2 (en) 2017-01-25
EP3119908A4 (en) 2018-02-21
MX2016011612A (es) 2016-12-12
WO2015135035A3 (en) 2016-09-15
SG10201807838SA (en) 2018-10-30
BR112016020897A2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
CN106661614A (zh) 确定癌症侵袭性、预后和治疗响应
Huang et al. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
US9670549B2 (en) Gene expression signatures of neoplasm responsiveness to therapy
US20160024596A1 (en) Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy
AU2017341084A1 (en) Classification and prognosis of cancer
JP2017532959A (ja) Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム
JP7043404B2 (ja) 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
JP2017508442A (ja) Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー
US20160032407A1 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
EP3102700A1 (en) Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
JP2017521058A (ja) 癌処置のための個別化三剤治療を選択するための方法
CN110225984A (zh) 鉴别癌症风险的方法和治疗选择
Charkiewicz et al. Gene expression signature differentiates histology but not progression status of early-stage NSCLC
Fernandez-Rozadilla et al. Tumor profiling at the service of cancer therapy
US20110320392A1 (en) Methods for predicting cancer response to egfr inhibitors
US20140329714A1 (en) Stat3 activation as a marker for classification and prognosis of dlbcl patients
EP2582848A2 (en) Prognostic and predictive gene signature for non-small cell lung cancer and adjuvant chemotherapy
Zhou et al. Tumor mutation burden determined by a 645-cancer gene panel and compared with microsatellite instability and mismatch repair genes in colorectal cancer
Cui et al. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone
Doisneau-Sixou et al. From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
Rotbauer Exploring the Role of Circulating Tumour Cell-Associated Genes in Estrogen Receptor-Positive Breast Cancer
Svensson The Tumour, the Host and Chemotherapy Response in Pancreatic Cancer
WO2025122992A1 (en) Cellular ancestry signatures for subtyping cancers priority
WO2017061953A1 (en) Invasive ductal carcinoma aggressiveness classification
Watza Immune-Centric Genetic Determinants of Lung Cancer Outcomes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170510